Health TrialsbyHealthPanel

Contribution of a* to Dental Bleaching After Combined Dental Bleaching

ConditionHealthy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Valencia

About this trial

A prospective, non-randomized, single-arm interventional clinical study with a before-after design will be conducted to assess changes in CIELab color parameters and the Whiteness Index for Dentistry (WID) following a standardized combined dental bleaching protocol. The study aims to evaluate the contribution of the a\* parameter (green-red axis) to overall dental whiteness.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 to 65 years

Good oral health

Presence of natural anterior teeth (incisors, canines, premolars)

Anterior teeth without restorations

Disqualifiers

Smoking

Previous tooth bleaching treatment

Pregnancy

Breastfeeding

Trial design

Design model

Single group

Treatments tested in this trial

  • Combined Dental Bleaching

    Procedure/Surgery

    The intervention consists of an in-office bleaching phase with two 20-minute applications of 40% hydrogen peroxide, followed by an at-home bleaching phase using 16% carbamide peroxide applied with custom trays for 90 minutes daily. Treatment will continue until color stabilization is achieved, defined as a change in WID of less than 2.6 units between two consecutive weekly measurements.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Combined Dental BleachingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Whiteness Index for Dentistry (WID)

Change in WID values calculated from CIELab parameters (L\*, a\*, b\*) between baseline and the end of treatment (up to 12 weeks).

Time frame
From baseline to end of treatment (up to 12 weeks).

Secondary outcomes

1

Change in L* parameter

Difference in L\* values between baseline and the end of treatment (up to 12 weeks) measured using spectrophotometry.

Time frame
Baseline to end of treatment (up to 12 weeks).
2

Change in a* parameter

Difference in a\* values between baseline and the end of treatment (up to 12 weeks), including assessment of sign changes.

Time frame
Baseline to end of treatment (up to 12 weeks).
3

Change in b* parameter

Difference in b\* values between baseline and the end of treatment (up to 12 weeks), measured using spectrophotometry.

Time frame
Baseline to end of treatment (up to 12 weeks)
4

Correlation between WID and CIELab parameters

Assessment of the relationship between changes in WID and changes in L\*, a\*, and b\*.

Time frame
At end of treatment (up to 12 weeks).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Valencia

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: